# Epstein-Barr Virus (EBV)-Specific T Cells as Therapy for Relapsed/Refractory EBV-positive Lymphomas

> **NCT00779337** · PHASE1 · COMPLETED · sponsor: **Queensland Institute of Medical Research** · enrollment: 8 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** Autologous AdE1- Latent Membrane Protein CTLs

## Key facts

- **NCT ID:** NCT00779337
- **Lead sponsor:** Queensland Institute of Medical Research
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2012-01
- **Final completion:** 2012-05
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2012-05-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00779337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00779337, "Epstein-Barr Virus (EBV)-Specific T Cells as Therapy for Relapsed/Refractory EBV-positive Lymphomas". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00779337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*